TSCAN THERAPEUTICS, INC. Operating Income
TSCAN THERAPEUTICS, INC. (TCRX) reported Operating Income of -$30.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
- TSCAN THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$30.49M.
- TSCAN THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$29.14M.
- TSCAN THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$23.86M.
- TSCAN THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$37.05M.
- TSCAN THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$135.81M.
- TSCAN THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$134.82M.
- TSCAN THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$93.46M.
- TSCAN THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$66.64M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$30.49M 10-Q · filed 2026-08-12 | -$59.63M 10-Q · filed 2026-08-12 | -$83.49M derived: sum of 3 quarters · filed 2026-08-12 | -$120.54M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$29.14M 10-Q · filed 2026-05-06 | -$53.00M derived: sum of 2 quarters · filed 2026-05-06 | -$90.05M derived: sum of 3 quarters · filed 2026-05-06 | -$128.70M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$23.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$60.91M derived: sum of 2 quarters · filed 2026-03-04 | -$99.56M derived: sum of 3 quarters · filed 2026-08-12 | -$135.81M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$37.05M 10-Q · filed 2025-11-12 | -$75.70M derived: sum of 2 quarters · filed 2026-08-12 | -$111.95M 10-Q · filed 2025-11-12 | -$148.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$38.65M 10-Q · filed 2026-08-12 | -$74.90M 10-Q · filed 2026-08-12 | -$111.61M derived: sum of 3 quarters · filed 2026-08-12 | -$144.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$36.25M 10-Q · filed 2026-05-06 | -$72.96M derived: sum of 2 quarters · filed 2026-05-06 | -$105.58M derived: sum of 3 quarters · filed 2026-05-06 | -$139.70M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$36.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$69.33M derived: sum of 2 quarters · filed 2026-03-04 | -$103.45M derived: sum of 3 quarters · filed 2026-03-04 | -$134.82M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$32.62M 10-Q · filed 2025-11-12 | -$66.74M derived: sum of 2 quarters · filed 2025-11-12 | -$98.11M 10-Q · filed 2025-11-12 | -$119.47M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$34.11M 10-Q · filed 2025-08-12 | -$65.49M 10-Q · filed 2025-08-12 | -$86.84M derived: sum of 3 quarters · filed 2025-08-12 | -$111.59M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$31.37M 10-Q · filed 2025-05-06 | -$52.73M derived: sum of 2 quarters · filed 2025-05-06 | -$77.48M derived: sum of 3 quarters · filed 2025-05-06 | -$102.09M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$21.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$46.10M derived: sum of 2 quarters · filed 2025-03-05 | -$70.72M derived: sum of 3 quarters · filed 2025-03-05 | -$93.46M 10-K · filed 2025-03-05 |
| 2023-09-30 | -$24.75M 10-Q · filed 2024-11-12 | -$49.36M derived: sum of 2 quarters · filed 2024-11-12 | -$72.10M 10-Q · filed 2024-11-12 | -$90.75M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$24.61M 10-Q · filed 2024-08-12 | -$47.35M 10-Q · filed 2024-08-12 | -$66.00M derived: sum of 3 quarters · filed 2024-08-12 | -$82.58M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$22.74M 10-Q · filed 2024-05-13 | -$41.39M derived: sum of 2 quarters · filed 2024-05-13 | -$57.97M derived: sum of 3 quarters · filed 2024-05-13 | -$73.22M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$18.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$35.23M derived: sum of 2 quarters · filed 2024-03-06 | -$50.47M derived: sum of 3 quarters · filed 2024-03-06 | -$66.64M 10-K · filed 2024-03-06 |
| 2022-09-30 | -$16.58M 10-Q · filed 2023-11-09 | -$31.82M derived: sum of 2 quarters · filed 2023-11-09 | -$47.99M 10-Q · filed 2023-11-09 | -$62.19M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$15.25M 10-Q · filed 2023-08-10 | -$31.41M 10-Q · filed 2023-08-10 | -$45.61M derived: sum of 3 quarters · filed 2023-08-10 | -$61.45M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$16.16M 10-Q · filed 2023-05-10 | -$30.36M derived: sum of 2 quarters · filed 2023-05-10 | -$46.21M derived: sum of 3 quarters · filed 2023-05-10 | -$56.89M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$14.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$30.04M derived: sum of 2 quarters · filed 2023-03-08 | -$40.72M derived: sum of 3 quarters · filed 2023-03-08 | -$48.64M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$15.84M 10-Q · filed 2022-11-09 | -$26.52M derived: sum of 2 quarters · filed 2022-11-09 | -$34.44M 10-Q · filed 2022-11-09 | -$42.25M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$10.68M 10-Q · filed 2022-08-10 | -$18.60M 10-Q · filed 2022-08-10 | -$26.41M derived: sum of 3 quarters · filed 2022-08-10 | -$33.58M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$7.92M 10-Q · filed 2022-05-12 | -$15.73M derived: sum of 2 quarters · filed 2022-05-12 | -$22.90M derived: sum of 3 quarters · filed 2022-05-12 | -$28.52M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$7.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$14.98M derived: sum of 2 quarters · filed 2022-03-09 | -$20.60M derived: sum of 3 quarters · filed 2022-03-09 | -$26.23M 10-K · filed 2022-03-09 |
| 2020-09-30 | -$7.17M 10-Q · filed 2021-11-10 | -$12.79M derived: sum of 2 quarters · filed 2021-11-10 | -$18.42M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$5.62M 10-Q · filed 2021-08-19 | -$11.25M 10-Q · filed 2021-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |